Therapeutic IgE Antibody Dosing to Reduce Systemic Hypersensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using IgG antibodies require high dosages for effective antigen presentation and T cell stimulation, leading to systemic hypersensitivity reactions, whereas IgE antibodies have shown potential but face challenges in bioactivity and biosafety due to their high affinity and potential for allergic reactions.
Innovation Solution
Administering therapeutic IgE antibodies in combination with immunostimulatory or chemotherapeutic agents to enhance bioactivity and biosafety, utilizing strategic dosing and administration protocols to induce localized immune responses and avoid systemic hypersensitivity, while targeting non-repetitive epitopes to minimize receptor crosslinking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dosages of IgG antibodies are administered for effective antigen presentation and T cell stimulation, then treatment efficacy is improved, but systemic hypersensitivity reactions occur
Solution Approach 1:
The patent changes the antibody class from IgG to IgE, which has fundamentally different binding characteristics. IgE antibodies bind with much higher affinity to FcεRI receptors on antigen-presenting cells, enabling effective antigen presentation and T cell stimulation at lower dosages, thereby avoiding the systemic hypersensitivity reactions associated with high-dose IgG administration
2Reliability
If IgE antibodies are administered to exploit their high affinity and potential for cancer treatment, then treatment potential is improved, but bioactivity and biosafety challenges arise due to allergic reactions
Solution Approach 1:
The patent employs targeted administration strategies where IgE antibodies are delivered locally to tumor sites or through targeted injection methods. This local delivery approach concentrates the therapeutic effect at the tumor microenvironment while minimizing systemic exposure, thereby reducing the risk of widespread allergic reactions while maintaining the high affinity benefits of IgE for cancer cell targeting
Solution Approach 2:
The patent implements premedication protocols and gradual dose escalation before administering IgE antibodies. Patients receive pre-treatment with antihistamines or corticosteroids to prevent allergic reactions, and the IgE antibody dosage is increased gradually over multiple administrations to allow the immune system to adapt, thereby mitigating biosafety concerns while enabling effective cancer treatment
3Object-affected harmful factors
If IgE antibodies target non-repetitive epitopes to minimize receptor crosslinking, then systemic hypersensitivity is reduced, but antigen presentation efficiency must be optimized
Solution Approach 1:
The patent selects IgE antibodies that target non-repetitive, unique epitopes on tumor antigens rather than repetitive structures. This epitope selection strategy prevents extensive crosslinking of FcεRI receptors that would trigger systemic allergic reactions. Simultaneously, the patent optimizes antigen presentation efficiency by ensuring the selected epitopes are effectively processed and presented by antigen-presenting cells, maintaining therapeutic efficacy while reducing hypersensitivity risk
Data Source
AI summary
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.